Dermata疗法在私人安排下筹集了410万美元,可能增加830万美元,用于资助丙烷产品的启动和创新。 Dermata Therapeutics raised $4.1 million in a private placement, with potential for $8.3 million more, to fund acne product launch and innovation.

Dermata Therapeutics完成了一项私募，筹集了410万美元的总收益，若行使认股权证，最高可获得830万美元。 Dermata Therapeutics closed a private placement raising $4.1 million in gross proceeds, with potential for up to $8.3 million more if warrants are exercised. 该公司出售了2,022,062份股份或预先供资的授权令,每份2.04美元,以及C系列和D系列授权令,可在股东批准后执行,并分别在5年零24个月内到期。 The company sold 2,022,062 shares or pre-funded warrants at $2.04 each, along with series C and D warrants exercisable after stockholder approval and expiring in five years and 24 months, respectively. 包括CEO和CFO在内的内幕人士也参加了讨论。 Insiders, including the CEO and CFO, participated. 收益将用于消费者研究,非经销商套件推出,技术收购和创新投资. Proceeds will fund consumer research, an OTC acne kit launch, technology acquisitions, and innovation investments. 对现有的授权令进行了修正,将其实际价格降低到每股2.04美元。 Existing warrants were amended to lower their exercise price to $2.04 per share. 该提议免予登记,并须有转售登记声明。 The offering was exempt from registration and subject to a resale registration statement.